InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
4,967.23
(
-0.88%
)
US TECH 100
16,554.00
(
-2.26%
)
Dow Jones
37,986.40
(
0.56%
)
Brent Oil
86.63
(
0.00%
)
Bitcoin
63,591.82
(
-0.37%
)
Post# of 251544
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

iwfal

Send PM Follow Ignore
Followers 75
Posts 4639
Boards Moderated 0
Alias Born 09/06/2003

iwfal

Member Level

Re: jq1234 post# 176915

Thursday, 04/17/2014 1:22:03 AM

Thursday, April 17, 2014 1:22:03 AM

Post# of 251544

Neither approval of Fabrazyme nor Myzoyme prevented subsequent placebo controlled ph3 trials.



As best I can tell the only randomized trials run after Fabrazyme approval were to expand the indication (e.g. to heterozygotes), different dosing schedules (no placebo) or in a different country. I.e. They didn't even try to enroll a placebo controlled trial in the approved population in the US.

Did I miss something?

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up